These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 6838691)

  • 1. The peripheral circulation and treatment of hyperlipoproteinemias.
    Coffman JD; Rasmussen HM
    Atherosclerosis; 1983 Jan; 46(1):147-59. PubMed ID: 6838691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of clofibrate and colestipol singly and in combination on plasma lipids and lipoproteins in type III hyperlipoproteinemia.
    Hoogwerf BJ; Peters JR; Frantz ID; Hunninghake DB
    Metabolism; 1985 Oct; 34(10):978-81. PubMed ID: 4046841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of colestipol when combined with clofibrate in the treatment of severe hyperlipidemia. Short-term and long-term studies.
    Lithell H; Vessby B; Boberg J; Hellsing K
    Atherosclerosis; 1980 Oct; 37(2):175-86. PubMed ID: 7000089
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of the effects of colestipol hydrochloride and clofibrate on plasma lipids and lipoproteins in the treatment of hypercholesterolemia.
    Seplowitz AH; Smith FR; Berns L; Eder HA; Goodman DS
    Atherosclerosis; 1981 Apr; 39(1):35-43. PubMed ID: 7018502
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofibrate-induced low density liporotein elevation. Therapeutic implications and treatment by colestipol resin.
    Rose HG; Haft GK; Juliano J
    Atherosclerosis; 1976; 23(3):413-27. PubMed ID: 178325
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of bezafibrate and colestipol on LDL-cholesterol, LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia.
    Kłosiewicz-Latoszek L; Nowicka G; Szostak WB; Naruszewicz M
    Atherosclerosis; 1987 Feb; 63(2-3):203-9. PubMed ID: 3827981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Colestipol, clofibrate, and phytosterols in combined therapy of hyperlipidemia.
    Grundy SM; Mok HY
    J Lab Clin Med; 1977 Feb; 89(2):354-66. PubMed ID: 833472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative efficacy of colestipol and clofibrate in type IIa hyperlipoproteinemia.
    Vecchio TJ; Linden CV; O'Connell MJ; Heilman J
    Arch Intern Med; 1982 Apr; 142(4):721-3. PubMed ID: 7073415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Colestipol, clofibrate, cholestyramine and combination therapy in the treatment of familial hyperbetalipoproteinaemia.
    Stein EA; Heimann KW
    S Afr Med J; 1975 Jul; 49(31):1252-6. PubMed ID: 168650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum lipoprotein lipids after gemfibrozil treatment.
    Schwandt P; Weisweiler P; Neureuther G
    Artery; 1979 Feb; 5(2):117-24. PubMed ID: 231950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of combined diet and colestipol in long-term (7--7 1/2 years) treatment of patients with type II hyperlipoproteinemia.
    Kuo PT; Hayase K; Kostis JB; Moreyra AE
    Circulation; 1979 Feb; 59(2):199-211. PubMed ID: 215338
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of clofibrate therapy on glucose tolerance, insulin secretion and serum lipids in subjects with hyperlipoproteinemia and impaired glucose tolerance. A follow-up study over a five-year period.
    Ratzmann ML; Rjasanowski I; Bruns W; Ratzmann KP
    Exp Clin Endocrinol; 1983 Aug; 82(2):216-21. PubMed ID: 6354731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pronounced lipoprotein lipid reduction obtained by combined lipid-lowering treatment in patients with atherosclerotic disease.
    Vessby B; Lithell H; Gustafsson IB; Borberg J
    Atherosclerosis; 1979 Aug; 33(4):457-77. PubMed ID: 228684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The treatment of hyperlipoproteinaemia with gemfibrozil compared with placebo and clofibrate.
    Nye ER; Sutherland WH; Temple Wa
    N Z Med J; 1980 Nov; 92(671):345-9. PubMed ID: 6935550
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination drug therapy for familial combined hyperlipidemia.
    East C; Bilheimer DW; Grundy SM
    Ann Intern Med; 1988 Jul; 109(1):25-32. PubMed ID: 3288029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical and biochemical parameters of patients with vascular stenosis in the lower extremities in the stage of intermittent claudication].
    Kozlovszky B; Mohácsi A; Bajnok L; Csiba L; Országh I; Fülöp T
    Orv Hetil; 1995 Apr; 136(16):817-22. PubMed ID: 7644187
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clofibrate treatment of hyperlipoproteinemia].
    Oikawa S; Midorikawa H
    Nihon Rinsho; 1994 Dec; 52(12):3285-91. PubMed ID: 7853724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary hypercholesterolemia: effect of treatment on serum lipids, lipoprotein fractions, cholesterol absorption, sterol balance, and platelet aggregation.
    Briones ER; Steiger D; Palumbo PJ; Kottke BA
    Mayo Clin Proc; 1984 Apr; 59(4):251-7. PubMed ID: 6708603
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutritional & pharmacologic management of hyperlipoproteinemia.
    Pickering JE
    Angiology; 1982 Sep; 33(9):577-80. PubMed ID: 6957154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of a clofibrate-inositol nicotinate combination on lipids and lipoproteins in primary hyperlipoproteinemia of types IIa, IV and V].
    Hutt V; Wechsler JG; Klör HU; Ditschuneit H
    Arzneimittelforschung; 1983; 33(5):776-9. PubMed ID: 6683558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.